Ibrutinib, a once-daily Bruton’s tyrosine kinase (BTK) inhibitor, received accelerated approval in the USA for patients with MCL who received ≥ 1 prior therapy [1, 2]. The gene discussed is BTK; the disease is mantle cell lymphoma.